Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Sammenligning av to oksygeneringsmål med to forskjellige oksymetre - innvirkning på oksygenstrømningshastigheter og oksygenering (Oxygap pong)

3. november 2026 oppdatert av: François Lellouche, Laval University

The investigators recently evaluated 4 different oximeters among the most commonly used with arterial catheter in place and compared SpO2 with SaO2 obtained on arterial gas. Correlations between SaO2 and SpO2 were poor for all oximeters, as previously known, and SpO2-SaO2 bias were different between oximeters. Some oximeters (Masimo, Nellcor) had lower biases but they detected less well hypoxemia. Some oximeters underestimated SaO2 (Nonin) but detected very well hypoxemia, and some overestimated SaO2 (Philips). The investigators concluded that oximeters provide different informations to clinicians, and oxygenation targets should take into account for these differences.

The assumption is that the SpO2 target AND oximeter used will both have an impact on oxygen flows and that these effects will add up. With a high SpO2 target, oxygen flows will be significantly greater and with the Nonin oximeter, the required flows will be greater than with the Philips oximeter.

NB: the results obtained were in a population with light skin pigmentation (96% of the patients were Fitzpatrick 1-2, reflecting the local hospitalized population).

Studieoversikt

Detaljert beskrivelse

The oximeters to be evaluated will be the Nonin (Plymouth, MN), and the Philips (Eindhoven, Netherlands). The sensors used will be digital reusable sensors for all oximeters. Because of the impact of the fingers used for SpO2 measurement, each oximeter will be randomly assigned a different finger to each patient (digit 2 and 3 on the hand opposite to the arterial catheter).

Two SpO2 targets will be assessed: 90% and 94%. A total of four 10-minute periods will be performed in randomized order: Nonin 90, Nonin 94, Philips 90, and Philips 94.

At the end of each 10-minute period, arterial gas will be collected through the arterial catheter.

The adjustment of the oxygen flow rates will be performed manually. The average oxygen flow of the last 2 minutes of the period will be considered.

Studietype

Intervensjonell

Registrering (Antatt)

40

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • ≥ 18 years of age
  • Patients admitted to postoperative cardiac surgery intensive care unit
  • Presence of an arterial catheter Specific for the extubate patient
  • Ongoing on conventional oxygen therapy at moderate flow (up to a maximum of 5L/min) with SpO2 between 88 and 100% with the usual oximeter and nasal cannula.
  • SpO2 < 92% ambient air Specific for the intubate patient FiO2 <= 0.60 with SpO2 between 88 and 100% with usual oximeter SpO2 < 92% with FiO2 0.21

Exclusion Criteria:

  • No SpO2 signal with oximeter in use
  • False nails or nail polish
  • Methemoglobinemia >0.015 on last available arterial gas
  • Patient in isolation (multi-resistant bacteria, C-Difficile, SARS-CoV-2 ...) Specific for the extubate patient
  • Expected to use another respiratory support within one hour of inclusion (NIV or nasal high flow oxygen) Planned extubation within one hour of inclusion

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Nonin oximeter with a 90% SpO2 target

During this periods , oxygen will be administered in an manual titration with the FreeO2 device (fixed flow mode) to reach 90% of SpO2.

Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Nonin oximeter

Eksperimentell: Philips oximeter with a 90% SpO2 target

During this periods, oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode), to reach 90% of SpO2.

Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Philips oximeter

Eksperimentell: Nonin oximeter with a 94% SpO2 target

During this periods , oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode) to reach 94% of SpO2.

Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter

Eksperimentell: Philips oximeter with a 94% SpO2 target

During this periods, oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode), to reach 94% of SpO2.

Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Oxygen flow (or FiO2)
Tidsramme: Mean Oxygen flow in the two last minute of each study period (between minute 8 and 10)

Oxygen flows (or FiO2) at the end of each study period (last minute average) to reach SpO2 target to reach SpO2 target with specific oximeter

Mean Oxygen flow in the two last minute of each study period (between minute 8 and 10)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Difference between SpO2 and SaO2
Tidsramme: assessed up to 10 minutes - at the same of the arterial blood gases punction

Difference (%) between SpO2 from each oximeter and SaO2 (% of SaO2 overestimation and underestimation for each oximeter)

assessed up to 10 minutes - at the same of the arterial blood gases punction

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Mean difference on oxymeter
Tidsramme: assessed up to 10 minutes - at the same of the arterial blood gases punction

Mean (±SD) of the gaps between the different oximeters tested

assessed up to 10 minutes - at the same of the arterial blood gases punction
Occult hypoxemia
Tidsramme: assessed up to 10 minutes - at the same of the arterial blood gases punction

Percentage of occult hypoxemia (SaO2<90% and SpO2>=90%)

assessed up to 10 minutes - at the same of the arterial blood gases punction
Occult hyperoxemia
Tidsramme: assessed up to 10 minutes - at the same of the arterial blood gases punction

Perrcentage of occult hyperoxemia (SaO2>96% and SpO2<=96%)

assessed up to 10 minutes - at the same of the arterial blood gases punction
Partial oxygen weaning
Tidsramme: Mean oxygen flow in the two last minute of each study period (between minute 8 and 10)

Rate of partial oxygen weaning (Oxygen flow <=0.5 L/min)

Mean oxygen flow in the two last minute of each study period (between minute 8 and 10)
Complete oxygen weaning
Tidsramme: Mean oxygen flow in the two last minute of each study period (between minute 8 and 10)

Rate of complete oxygen weaning (Oxygen flow =0 L/min or FiO2 0.21)

Mean oxygen flow in the two last minute of each study period (between minute 8 and 10)
Respiratory support escalation
Tidsramme: Mean oxygen flow in the two last minute of each study period (between minute 8 and 10)

Indication of initiation of respiratory support escalation (Oxygen flow >6 L/min or FiO2 > 0.60)

Mean oxygen flow in the two last minute of each study period (between minute 8 and 10)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

16. november 2022

Primær fullføring (Antatt)

1. juni 2027

Studiet fullført (Antatt)

1. desember 2027

Datoer for studieregistrering

Først innsendt

14. oktober 2022

Først innsendt som oppfylte QC-kriteriene

18. oktober 2022

Først lagt ut (Faktiske)

21. oktober 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 22266

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere